Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 01/26 | 01/28 | 3,746 sh | $37.15 | $139,163.9 | −13.3% | |
Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 01/15 | 01/20 | 20,961 sh | $35.92 | $752,919.12 | −100.0% | |
Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/12/12 | 25/12/17 | 25,933 sh2 trades | $40.11avg. | $1,040,172.63 | −100.0% | |
Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/12/05 | 25/12/09 | 20,000 sh | $39.54 | $790,800 | −100.0% | |
Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/11/21 | 25/11/25 | 3,427 sh | $35.00 | $119,945 | −100.0% | |
Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/08/15 | 25/08/19 | 21,573 sh | $36.50 | $787,414.5 | −100.0% | |
Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/04/01 | 25/04/03 | 6,987 sh2 trades | $32.55avg. | $227,411.36 | −100.0% | |
Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/03/03 | 25/03/05 | 4,869 sh2 trades | $32.67avg. | $159,088.09 | −100.0% | |
Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/01/27 | 25/01/28 | 1,775 sh | $38.05 | $67,538.75 | −100.0% | |
Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/01/24–25/01/27 | 25/01/28 | 14,754 sh3 trades | $37.38avg. | $551,538.33 | −100.0% | |
Jeffrey M. DaynoPresident, CEO | Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/01/21 | 25/01/23 | 19,293 sh | $40.13 | $774,228.09 | −100.0% |
Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/01/21 | 25/01/23 | 25,000 sh | $40.18 | $1,004,500 | −100.0% | |
Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/01/16–25/01/21 | 25/01/21 | 30,598 sh2 trades | $37.51avg. | $1,147,579.75 | −100.0% | |
Jeffrey DierksChief Commercial Officer | Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/01/15 | 25/01/16 | 10,507 sh | $37.01 | $388,864.07 | −100.0% |
Jeffrey DierksChief Commercial Officer | Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 25/01/13 | 25/01/15 | 7,180 sh | $37.04 | $265,947.2 | −100.0% |
Harmony Biosciences HoldingsHRMY | Open-market sale | 24/11/01–24/11/05 | 24/11/05 | 4,600,000 sh2 trades | $30.30avg. | $139,380,000 | −41.0% | |
Harmony Biosciences HoldingsHRMY | Open-market sale | 24/11/01–24/11/05 | 24/11/05 | 4,600,000 sh2 trades | $30.30avg. | $139,380,000 | −43.2% | |
Jeffrey DierksChief Commercial Officer | Harmony Biosciences HoldingsHRMY | Open-market sale10b5-1 plan | 24/10/29 | 24/10/31 | 21,496 sh | $40.47 | $869,943.12 | −100.0% |
Harmony Biosciences HoldingsHRMY | Open-market sale | 24/10/03 | 24/10/07 | 36,357 sh2 trades | $35.06avg. | $1,274,714.7 | −100.0% | |
Jeffrey DierksChief Commercial Officer | Harmony Biosciences HoldingsHRMY | Open-market sale | 24/10/01 | 24/10/02 | 400 sh | $40.19 | $16,076 | −100.0% |